ImExHS Valuation
Is IME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IME?
Other financial metrics that can be useful for relative valuation.
| What is IME's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | AU$23.41m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | -19.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does IME's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.6x | ||
DOC Doctor Care Anywhere Group | 0.3x | 30.1% | AU$18.0m |
GLH Global Health | 1.3x | n/a | AU$9.0m |
PCK PainChek | 22.7x | n/a | AU$33.7m |
TD1 TALi Digital | 5.2x | n/a | AU$4.9m |
IME ImExHS | 1.4x | 21.2% | AU$23.4m |
Price-To-Sales vs Peers: IME is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (7.6x).
Price to Earnings Ratio vs Industry
How does IME's PE Ratio compare vs other companies in the AU Healthcare Services Industry?
Price-To-Sales vs Industry: IME is good value based on its Price-To-Sales Ratio (1.4x) compared to the Australian Healthcare Services industry average (5.2x)
Price to Sales Ratio vs Fair Ratio
What is IME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | 1.3x |
Price-To-Sales vs Fair Ratio: IME is expensive based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).
Share Price vs Fair Value
What is the Fair Price of IME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IME's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.